Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
October 2017
-
Media ReleaseAlcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOLAutonoMe(TM) preloaded IOL delivery system provides easy, intuitive control for precise IOL insertion during cataract surgery New Clareon® IOL in vitro data and early clinical experience to…
-
Talking to: Patrice Matchaba, Global Head of Corporate Responsibility for Novartis
Dr. Matchaba describes how his unique background can help guide the company’s access-to-medicine efforts.
-
Media ReleaseAlcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congressClareon® intraocular lens (IOL) implanted with a unique single-use automated pre-loaded delivery system debuts with new data presentations Congress program highlights Alcon's 70-year legacy…
September 2017
-
Living with hypertension in Cameroon on a few dollars per day
In Cameroon, seeking treatment for chronic diseases can be a long journey.
-
Novartis and UC Berkeley take on “undruggable” proteins in new collaboration
Researchers from industry and academia will leverage new chemistry to hit difficult drug targets.
-
In The NewsNovartis Access and government of Cameroon sign agreement to fight chronic diseasesCameroon faces a serious increase in chronic diseases like heart disease, asthma, cancer and diabetes. This agreement complements the government’s ongoing efforts by improving access to affordable…
-
Media ReleaseNovartis and UC Berkeley collaborate to tackle 'undruggable' disease targetsCollaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer New Novartis-Berkeley Center for Proteomics and…
-
Media ReleaseNovartis and The Max Foundation transform pioneering cancer access program for people in lower-income countriesCMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model GIPAP was introduced 15 years ago and has…
-
Media ReleaseNovartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)Significant overall survival benefit seen with Rydapt, the first targeted treatment for newly diagnosed FLT3-mutated AML approved in the EU[1] As the first and only therapy for advanced SM…
-
Led by Steven Taylor, the Sjögren’s Syndrome Foundation is raising awareness of a little-known autoimmune disease
-
Media ReleaseNovartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruptionOPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled[1] Should a treatment pause be necessary, data showed almost…
-
Media ReleaseSandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile[1]Sandoz proposed biosimilar adalimumab is currently under…
Pagination
- ‹ Previous page
- 1
- …
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- …
- 151
- › Next page